过去一年中添加的文章，按日期排序
Pharmacokinetic study of erlotinib in a pregnant woman with advanced non‐small cell lung cancer and observation of the effects on the child growth
Y Aida, M Ohgami, Y Mukai, M Matsuyama… - British Journal of … - Wiley Online Library
3 天前 - … The aim of this case report is to describe the pharmacokinetics and placental
transfer of erlotinib in a pregnant woman with lung cancer treated with this medication during the …
transfer of erlotinib in a pregnant woman with lung cancer treated with this medication during the …
Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant NSCLC
안병철， 박찬이， 김문수， 이종목， 최진호… - Cancer Research and …, 2024 - kiss.kstudy.com
6 天前 - … small cell lung cancer (NSCLC); however, their effects on the tumor microenvironment
(TME) are unknown. We assessed the changes induced by neoadjuvant erlotinib therapy …
(TME) are unknown. We assessed the changes induced by neoadjuvant erlotinib therapy …
Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials
B Mangla, P Mittal, P Kumar, G Aggarwal - Medical Oncology, 2024 - Springer
8 天前 - … ELB was approved by the US Food and Drug Administration (FDA) in 2004 for
advanced non-small cell lung cancer (NSCLC) treatment in patients who relapsed after at least …
advanced non-small cell lung cancer (NSCLC) treatment in patients who relapsed after at least …
Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis
S Zhou, N Kishi, P Alerasool, NC Rohs - Targeted Oncology, 2024 - Springer
19 天前 - … The risk of high-grade rash was significantly increased in patients treated with
erlotinib or gefitinib (Table 3 of the ESM; Fig. 3A). In subgroup analyses based on the control arm, …
erlotinib or gefitinib (Table 3 of the ESM; Fig. 3A). In subgroup analyses based on the control arm, …
[HTML][HTML] Simultaneous Acquisition of T790M Mutation and SCLC Transformation during Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma: A Rare Case …
T Yazaki, M Kimoto, A Minagawa… - The American Journal …, 2024 - ncbi.nlm.nih.gov
19 天前 - … of non-small cell lung cancer transform into small cell lung carcinoma (SCLC) during
… During treatment with erlotinib, the patient developed SCLC and adenocarcinoma with …
… During treatment with erlotinib, the patient developed SCLC and adenocarcinoma with …
[引用][C] CO161 Adherence and Persistence To Oral Targeted Therapies for Non-Small-Cell Lung Cancer and Association With Survival Outcomes
S Nduaguba, A Cipoletti, R Misra - Value in Health, 2024 - valueinhealthjournal.com
20 天前 - Objectives Since the early 2000s, several oral targeted therapies (OTTs) have been
approved by the FDA for the treatment of non-small-cell lung cancer (NSCLC). OTTs have …
approved by the FDA for the treatment of non-small-cell lung cancer (NSCLC). OTTs have …
EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non–small cell lung cancer
C Yang, S Ma, J Zhang, Y Han, L Wan… - Proceedings of the …, 2024 - National Acad Sciences
22 天前 - … of lung adenocarcinoma to small cell lung cancer (SCLC) … to erlotinib in NE
transformation cell lines and cell-derived … SCLC samples obtained from clinical patients. …
transformation cell lines and cell-derived … SCLC samples obtained from clinical patients. …
Preclinical development of ATR04-484, an auxotrophic strain of Staphylococcus epidermidis, for the topical treatment of epidermal growth factor receptor (EGFR) …
TM Whitfill, S Mootien, R Leger - 2024 - ascopubs.org
22 天前 - … To evaluate the anti-inflammatory effects of ATR04-484, IL-36γ levels were measured
on untreated RHE and RHE treated with erlotinib alone or in combination with ATR04-484…
on untreated RHE and RHE treated with erlotinib alone or in combination with ATR04-484…
Disulfidptosis‑related lncRNA prognosis model to predict survival therapeutic response prediction in lung adenocarcinoma
X Sun, J Li, X Gao, Y Huang, Z Pang… - Oncology …, 2024 - spandidos-publications.com
23 天前 - … in the high‑risk group were more sensitive to treatment with crizotinib, erlotinib …
cell lung cancer (NSCLC) comprises ~85% of all lung cancer cases, with almost 60% of patients …
cell lung cancer (NSCLC) comprises ~85% of all lung cancer cases, with almost 60% of patients …
Real-world outcomes of osimertinib (Osi) vs. afatinib or erlotinib in patients with classical vs. atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).
23 天前 - … Real-world analyses comparing osi to afatinib and erlotinib for AM have yielded
mixed results. Methods: We performed a single-institution retrospective analysis of patients with …
mixed results. Methods: We performed a single-institution retrospective analysis of patients with …